Apple's attempts to overturn a $634 million patent verdict and secure a new trial in its dispute with Masimo have been denied. Masimo, a medical technology company, sued Apple in 2020, alleging trade secret theft and patent infringement related to Apple Watch health-monitoring technologies.

In 2023, an International Trade Commission ruling led to an import ban on certain Apple Watch models, prompting Apple to temporarily halt sales or disable the blood oxygen feature. Apple later introduced a redesigned feature. Meanwhile, a separate patent lawsuit proceeded, and in November 2025, a jury found Apple Watch features infringed a Masimo patent, awarding $634 million in damages.

U.S. District Judge James V. Selna rejected Apple's challenge, upholding the jury's finding that the Apple Watch can be considered a patient-monitoring device under Masimo's patent. Apple's arguments that the term should only apply to conventional medical equipment were dismissed, as the judge sided with the patent's broader interpretation. Judge Selna also denied Apple's request for a new trial, finding no significant errors in jury instructions or expert testimony exclusion.